Portal de Periódicos da CAPES

High-dose trivalent influenza vaccine. Efficacy and effectiveness

2020; Sociedad Española de Quimioterapia; Volume: 33; Issue: 4 Linguagem: Inglês

10.37201/req/043.2020

1988-9518

Ángel Gil de Miguel, Esther Redondo Margüello, Javier Díez‐Domingo, Raúl Ortíz de Lejarazu, Federico Martinón‐Torres,

SARS-CoV-2 and COVID-19 Research

Seasonal influenza is a major public health problem, particularly in older people. Influenza vaccine is the most effective way to prevent influenza virus infection and its complications, but due to immunosenescence, older people do not respond efficiently to immunization. In 2009, a high-dose trivalent influenza vaccine (IIV3-HD), containing four times more antigen than the standard-dose vaccine, was approved in the United States for the immunization of people aged 65 years and over. Numerous clinical trials, carried out at different seasons and using different methodologies, have shown that the IIV3-HD vaccine is, as well as safe, more immunogenic and more effective than the standard-dose vaccine in preventing influenza virus infection and its complications in older people. This paper reviews the available evidence on the efficacy and effectiveness of the IIV3-HD influenza vaccine in the elderly, with information from randomized clinical trials, as well as observational studies of real-world clinical practice and in systematic reviews/meta-analyses.